Full Text View
Tabular View
No Study Results Posted
Related Studies
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-Tenascin Radiolabeled Antibody Therapy (Glass-Art)
This study is ongoing, but not recruiting participants.
Study NCT00615186   Information provided by Bradmer Pharmaceuticals Inc.
First Received: February 1, 2008   Last Updated: April 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Glioblastoma Multiforme
Additional conditions recognized in this trial
Glioblastoma
More general conditions related to this trial
Astrocytoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
Radiation Therapy + Temozolomide
Additional drug interventions recognized in this trial
Dacarbazine
Immunoconjugates
Temozolomide
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Bradmer Pharmaceuticals Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services